Pharmacokinetics and pharmacodynamics of a new recombinant FⅧ in haemophilia A mice

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户：hfutnyd

【摘要】

：

Aims:To evaluate the pharmacokinetics and pharmacodynamics properties of a new recombinant factor Ⅷ (rFⅧ), which was produced and formulated without human or animal-derived protein, and compare it wit

【作者】

：

Ruolan GU Liang LIU Xiaoxia ZHU Zhiyun MENG Hui GAN Zuona WU Guifang DOU

【机构】

：

State Key Laboratory of Drug Metabolism, Hematological Pharmacology, Beijing Institute of Transfusio

【出处】

：

第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu

【发表日期】

：

2013年4期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

他克莫司不良反应的文献分析及诱发因素的探讨

目的了解免疫抑制剂他克莫司不良反应的总体情况，综合评估其临床应用的安全性，并针对可能引起不良反应的主要相关因素进行探讨。方法检索维普中文科技期刊数据库、万方数据库及中国期刊全文数据库(2000～2013年)的他克莫司不良反应相关文献，对患者性别、年龄、他克莫司血药浓度、不良反应发生时问、临床表现、处置及转归进行汇总，最后对引起不良反应的诱发因素进行分析和讨论。结果共纳入中文文献37篇，涉及病

会议

他克莫司不良反应诱发因素血药浓度

丙戊酸在癫痫患儿中的群体药动学与个体化给药

目的：建立丙戊酸(Valproic acid,VPA)在中国癫痫忠儿体内的群体药物动力学模型,基于模型采用贝易斯反馈法制定个体化的给药方案.方法：回顾性收集2011年5月至2013年5月在北京天坛医院住院并服用VPA常规治疗癫痫患儿的临床资料与血药浓度数据,采用非线性混合效应模型法(nonlinear mixed effect modeling,NONMEM)建立丙戊酸在上述人群中的群体药物动力学

会议

丙戊酸癫痫群体药物动力学个体化给药

Polymorphisms in dihydropyrimidine dehydrogenase influence the chemotherapeutic toxicity of 5-Fu

Objective To explore the relationship between single nucleotide polymorphisms (SNP) of dihydropyrimidine dehydrogenase (DPD) and chemotherapeutic toxicity of 5-Fluorouracil (5-Fu) in patients with gas

会议

5-Fluorouracildihydropyrimidine dehydrogenasesingle nucleotide polymorphismsc

The effect of CYP3A polymorphisms on cyclosporine individual dosage regimen and blood concentration

OBJECTIVE The present study was aimed to evaluate whether the interindividual variation of cyclosporine dosages and blood concentration were associated with CYP3A4 and CYP3A5 polymorphism in renal tra

会议

cyclosporinegenetic polymorphismCYP3A4CYP3A5

Personalized Medicine Based on the Population Pharmacokinetics of Valproic Acid in Children with Epi

OBJECTIVE:To realize personalized medicine on the basis of population pharmacokinetics (PopPK) of valproic acid (VPA) in children with epilepsy.METHODS:The clinical data and VPA plasma concentrations

会议

Identification of Factors Influencing the Pharmacokinetics of Voriconazole and the Optimization of D

Objective: The objective of this study is to estimate the population pharmacokinetics of voriconazole, to identify the factors influencing voriconazole pharmacokinetics, and to identify optimal dosage

会议

Development and validation a PBPK model to predict age-dependent PK for Chinese subjects-a case stud

Aim:Todevelop and validate a general physiologicallybased pharmacokinetic (PBPK) model for hepatic pathway in Chinese adults at various ages, and to evaluate it with midazolam (substrate of CYP3A4) as

会议

Population pharmacokinetic analysis of icotinib in Chinese healthy subjects

Objective:Icotinib is a potent small-molecule inhibitor of epidermal growth factor receptor (EGFR)-tyrosine kinase (TKI), which was designed for the treatment of non-small cell lung cancer (NSCLC).It

会议

Prediction of Drug Disposition in Diabetic Patients by Means of Physiologically Based Pharmacokineti

Accumulating evidences have showed that pharmacokinetics of some drugs was altered by diabetes mellitus, leading to changes of pharmacodynamic/toxic effects.Pro-dosage prediction ofpharmacokinetics wa

会议

A semi-mechanistic population pharmacokinetic model describing the time-dependent kinetics of Red Bl

Background: XQ (Carfree, Nanjing, China), a new chemical entity that possesses pharmacological activity on PlateletActivating Factor (PAF).XQ was approved into phase Ⅰ evaluation for treatment of isch

会议

Pharmacokinetics and pharmacodynamics of a new recombinant FⅧ in haemophilia A mice

与本文相关的学术论文